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Abstract: Doping with performance enhancing substances in professional and amateur sports has 
increasingly gained awareness. Furthermore, not only the number but also the variety of substances 
detected in sports has increased. Intending muscle growth, anabolic androgenic steroids (AAS) have 
been complemented by selective androgen receptor modulators (SARMs), β2-adrenergic agonists, 
estrogen receptor (ER) β agonists and peptide-hormones like growth hormone (GH), insulin-like 
growth factor-1 (IGF-1) and insulin. However, with respect to therapeutic use, drugs which increase 
anabolic actions in the body are highly desired for treatment of cachexia, sarcopenia, etc. 
The aim of the following review is to elaborate on the agents’ similarities and differences in 
mechanisms inducing muscle hypertrophy while giving an overview of the relevant signalling 
cascades. In addition to that, potential agents for treatment of catabolic diseases are identified. 
Information, on which this paper is based on, has been collected from various publications which 
have been published in high-quality scientific journals. 
The insight obtained has shown that signalling pathways mediating genomic actions of steroids 
have already been well-characterised, while there is still need for further research on the mechanisms 
of non-genomic actions and downstream pathways as well as on those of SARMs and β2-adrenergic 
agonists’ action. A new and promising target is the estrogen receptor β. The use of ER-β agonists, 
which are proposed to activate anabolic mechanisms independently from androgen receptor 
activation, may prevent the non-desired androgenic effects, which are associated with AAS 
administration. Thus, they may be considered a promising alternative for treatment of diseases, 
which cause loss of muscle mass and cachexia. In this context, phytoecdysteroids, such as 
ecdysterone etc, are considered as an interesting class of substances, where further investigations are 
highly desired. Furthermore, some peptide hormones also promote muscle hypertrophy. The 
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signalling mechanisms of growth hormone, IGF-1 and insulin are summarised. Finally, the potential 
of myostatin inhibition is discussed. 
Keywords: muscle hypertrophy; performance enhancement; signalling cascades; doping agents; 
anabolic-androgenic steroids; beta-2-adrenergic agonists; peptide hormones 
 
Abbreviations: 4E-BP1: 4E binding protein-1; AAS: anabolic androgenic steroids; AC: 
adenylylcyclases; ActRIIB: activin type IIB receptor; ALK4/5: activin-like kinase 4/5; AR: androgen 
receptor; ARE: androgen-response-elements; ATP: adenosine triphosphates; BAD: Bcl-associated 
death agonist; BMP: bone morphogenetic protein; cAMP: cyclic adenosine-monophosphate; cIGF-1: 
circulating IGF-1; CBP: CREB-binding protein; COPD: chronic obstructive pulmonary disease; CpG: 
cytosine-phosphate-guanine; CRE: cAMP response element; CREB: cAMP response element 
binding protein; DMD: Duchenne muscular dystrophy; EGFR: endothelial growth factor receptor; 
Epac1: exchange protein directly activated by cAMP 1; ER: estrogen receptor; ERK: extracellular 
signal-regulated protein kinase; FLG: follistatin related gene; FOXO: forkhead O transcription factor; 
FSH: follicle stimulating hormone; GASP: growth and differentiation factor-associated serum 
protein-1; GH: growth hormone; GHRH: growth hormone releasing hormone; GnRH: gonadotropin 
releasing hormone; GPCR: G-protein coupled receptor; GR: glucocorticoid receptor; GSK-3: 
glycogen synthase kinase 3; HAT: histone acetyl transferase; HDAC: histone deacetylase; HMB: 
β-hydroxy-β-methylbutyrate; HPA: hypothalamic pituitary gonadal axis; HSP: heat-shock-protein; 
iAR: intracellular androgen receptors; IGF-1: insulin-like growth factor-1; IGF-1R: insulin-like 
growth factor-1 receptor; IL-25: interleukin 25; IR: insulin receptor; IRS: 
insulin-response-substrate; LH: luteinizing hormone; MAFbx: muscle atrophy F-box protein; 
MAPK: mitogen-activated protein kinase; mAR: membrane-located androgen receptors; MEK: 
MAP-Erk-Kinase; mIGF-1: muscular IGF-1; MLC: myosin light-chain; MuRF1: muscle ring 
finger protein 1; MyoD: myoblast determination protein; NARI: selective noradrenaline reuptake 
inhibitor; NFAT: nuclear factors of activated T-cells; NOR1: neuron-derived orphan receptor 1; 
p70s6K: p70 ribosomal protein S6 kinase; PI3K: phosphatidylinositol-3-phosphat kinase; PIP2: 
phosphatidylinositol-4,5-bisphosphate; PIP3: phosphatidylinositol-3,4,5-trisphosphate; PKA: 
proteinkinase A; PPAR-gamma: peroxisome-proliferator activated receptor-gamma; Prmt7: protein 
arginine methyltransferase 7; PSA: prostate specific antigen; p/CAF: p300/CBP-associated factor; 
SARM: selective androgen receptor modulator; SERM: selective estrogen receptor modulators; 
SHBGR: sex hormone-binding globulin receptor; STEAR: selective tissue estrogenic activity 
regulator; SRC: steroid receptor coactivator; TGF-β: transforming growth factor β; WADA: World 
Anti-Doping Agency 
1. Introduction 
Various substance classes are misused to enhance performance in competitive sports. Current 
regulations in sports are based on the World Anti-Doping Code, where doping is (among others) 
defined as use of a prohibited substance or the application of a prohibited method [1]. 
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The most commonly detected doping agents are anabolic androgenic steroids (AAS). They are 
either chemically and biologically related to the physiological male sex hormone testosterone or 
testosterone itself [2]. As already indicated by their name, they have anabolic effects, thus promoting 
muscle mass increase. These substances can be naturally occurring compounds or synthetically 
modified derivatives which have been chemically altered mainly with the intention of increasing 
anabolic properties while simultaneously decreasing androgenic adverse effects but also for altering 
pharmacokinetic properties [3]. Increased muscle fibre size and myosatellite cell numbers have been 
reported after AAS administration in rats [4]. The signalling pathways resulting from the agents’ 
binding to androgen receptors (AR) can be divided in genomic [3,5–8] and rapid, non-genomic 
actions, from which mechanisms have not yet been fully understood [5,6,9–15]. In addition to that, 
AAS are reported to inhibit catabolic properties of glucocorticoids by blocking the binding of 
endogenous ligands to glucocorticoid receptors (GR) [6,16–19]. All of these mechanisms are 
supposed to result in muscle hypertrophy and a decrease in catabolic activities, although there is still 
lack of evidence for an AAS mediated increase in protein synthesis and athletic performance [3]. 
One scientific study reports increased performance in bench-press and squatting exercises [20]. This 
placebo controlled investigation reported a significant increase upon testosterone administration 
(testosterone enanthate 600 mg/week for six weeks, intramuscular). This effect is even more 
pronounced if combined with training. Adverse effects resulting from misuse of AAS include 
alteration of blood lipid levels and coagulation factors, related to various severe cardiovascular 
events such as stroke, embolism, cardiomyopathy, myocardial hypertrophy, hepatotoxicity, 
nephrotoxicity, and dermatological disorders like acne as well as effects regarding the central 
nervous system, e.g., depression and general behavioural changes [6,8,21–26]. Sex-specific side 
effects are virilisation in women associated with alterations in body hair, deepening of the voice, 
enlarged clitoris, some of them permanent, and gynaecomastia in males [6,27–29]. Alterations of 
sexual function and infertility is also associated with the administration of AAS [29,30]. In 
adolescents, accelerated bone maturation and closure of the epiphyseal growth zones with growth 
retardation is reported [31]. 
In addition to androgen receptor mediated anabolic conditions in tissues, estrogen receptor 
(ER) β (ER-β) has also been suggested to catalyse muscle hypertrophy and other metabolic 
changes [32,33], e.g., an increased immune response and activation of satellite cells [34,35], while 
estrogen receptor α (ER-α) does not seem to have relevant impact in mediating anabolic actions [33]. 
Both ER subtypes are generated from different genes and show differences in their expression 
pattern in various tissues [36]. Weigt et al. propose ER-α to be relevant for regulating blood lipids 
while ER-β is thought to mediate remodelling in muscle tissue [37]. Adipose tissue is presumed to be 
influenced by both receptor-subtypes [34]. 
The development of selective androgen receptor modulators (SARMs) was encouraged by the 
successful production of selective estrogen receptor modulators (SERMs) like tamoxifen, which are 
used in the treatment of breast cancer, and the selective tissue estrogenic activity regulator (STEAR) 
tibolone, which can be used to treat menopausal symptoms and endometriosis [38]. Thus, targeting 
the androgen receptor, also SARMs are developed intending to promote anabolic effects while not 
affecting reproductive tissues [39]. However, in contrast to the estrogen receptor, where two different 
subtypes (ER-α and ER-β) are identified, no subtypes of the AR are known. Nevertheless, tissue 
selectivity in SARMs could possibly be achieved, but until now none of the currently developed 
SARMs was found truly selective for muscle and bone tissues in comparison to the reproductive 
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tissues [39]. In addition to beneficial tissue selectivity, new small-molecule SARMs without 
steroid backbones are considered to ease the development of dosage forms and allow oral 
administration [40]. However, even if the intention of SARM design was to achieve muscle 
hypertrophy and bone consolidation while reducing the adverse effects associated with AAS use, it 
was observed that also after SARMs administration, hematocrit, blood pressure, blood lipid and 
hormone levels, i.e., total testosterone, luteinizing hormone (LH) and follicle stimulating hormone 
(FSH) levels, were significantly altered [26]. Until now, most of these compounds failed to advance 
to clinical development either due to toxicity or lack of efficacy, or other undisclosed reasons [39]. 
By now, a few clinical trials are ongoing, e.g., on enobosarm (GTx-024) and LY2452473 (both 
phase II, according to www.clinical trials.com, accessed Nov 26th, 2017). 
In various animal models, β2-adrenergic agonists like clenbuterol lead to increase in muscle 
growth, lipid mobilisation in fat tissue and other metabolic effects [41]. In contrast to other agents, 
these effects seem to depend on the route of application [42]. In animal husbandry, β2-adrenergic 
agonists are known as growth promoting and repartition agents and their illegal use in meat 
production is reported in several publications. It is also shown that this misuse in animals, especially 
in case of the highly active clenbuterol, may have an impact on humans through consumption of 
meat, as well. It has even led to poisoning in men due to the consumption of contaminated meat 
products [43–51]. Signalling via β2-adrenergic agonists is mediated through binding to a Gα-protein 
coupled receptor (GPCR), leading to activation of adenylylcyclase (AC) and production of cyclic 
adenosine-monophosphate (cAMP), which then leads to an activation of proteinkinase A and 
phosphorylation of various effector proteins [41,52]. 
Apart from the small molecule drugs discussed before also some peptide or protein drugs are 
listed as prohibited substances in sports according to the regulations of the World Anti-Doping 
Agency (WADA) as separate class S2 “Peptide Hormones, Growth Factors, Related Substances and 
Mimetics” [53]. Out of this class, several compounds are also involved in the promotion of muscle 
growth: Gonadotrophins act as stimulators of steroid hormone production, thereby increasing the 
endogenous production of androgens in the effector cells. Somatotropin (growth hormone, GH) is 
considered to act as physiological precursor of insulin-like growth factor-1 (IGF-1), inducing IGF-1 
liberation into the blood stream [54]. Evidence is increasing, that IGF-1 subsequently binds to IGF-1 
receptors on the surface of muscle cells, inducing growth via several pathways, including the 
phosphatidylinositol-3-phosphate kinase (PI3K)/protein kinase B (Akt) pathway [55]. Further 
growth factors are included in the list of prohibited substances in sports as well. Covered in a 
different class, insulin and its analogues are also prohibited in sports, mainly due to their effect 
of altering metabolic activities and energy supply. However, reports on pathways promoting 
muscle growth by insulin are also reported. A strong link between insulin and IGF-1 actions is 
seen in the phosphorylation of insulin response substrate (IRS) [35,56]. Sudies report 
β-hydroxy-β-methylbutyrate (HMB) as inducer of GH and IGF-1. However, a recent review of 
Holeček mentioned that the hypertrophic effect of HMB on muscles is especially relevant in 
elderly subjects and if combined with exercise [57]. 
Another strong (negative) regulator of muscle growth is myostatin, a member of the 
transforming growth factor β (TGF-β) superfamily [58–60]. It is reported to inhibit myoblast 
proliferation and differentiation [61–64]. Upregulation of myostatin results in muscle atrophy [65], 
which is also reported as effect after glucocorticoid administration or neuron-derived orphan 
receptor 1 (NOR1) inhibition [66,67]. Consequently, the inhibition of myostatin results in increases 
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in muscle growth [68]. Reports on myostatin deficient mice, cattle and even humans display its 
strong effect and underline the potential of myostatin inhibition as therapeutical option [59–74]. 
However, there is also evidence that myostatin inhibition may only result in early improvement, 
while progression of muscle degeneration still continues later on [75]. 
Deeper knowledge of the signalling mechanisms mediated by the different substance classes are 
not only important for identifying characteristics of those substances that are illegally used by 
athletes in order to enhance their performance. They can also be of therapeutic value in treatment of 
patients suffering from muscle wasting syndromes, i.e., cachexia, muscle atrophy, frailty or 
sarcopenia [76–82]. Patients suffering from diseases like cancer, AIDS, chronic obstructive 
pulmonary disease (COPD), rheumatoid arthritis, diabetes, heart or renal failure, may develop 
cachexia, which is also associated with increased incidence of morbidity and mortality [83,84]. 
Additionally, muscle wasting is associated with an increased risk of developing metabolic diseases, 
such as metabolic syndrome or type-2 diabetes [85]. Current therapeutic strategies mainly focus on 
adaptation of nutrition to high protein diet and regular physical exercises, but severe cases may also 
profit from pharmacotherapy involving one of the substance classes mentioned in this review. 
2. Mechanism of action 
2.1. Anabolic-androgenic steroids (AAS) 
Signalling mechanisms, by which AAS modulate human tissues can be divided in genomic and 
rapid, non-genomic actions [5,14]. Genomic actions include changes in AR expression and 
interaction with co-activators, resulting in transcription of specific target genetic regions [6]. In 
addition, an anti-catabolic effect by interference with native agonists to glucocorticoid receptors, 
inhibiting their binding, is suggested [6,16]. Non-genomic actions are supposed to result in activation 
of second messenger signal transduction cascades, providing multiple changes within a few 
minutes [7,14]. 
2.1.1. Genomic actions of AAS 
Genomic actions are mediated by binding of testosterone or the respective derivative to 
intracellular androgen receptors (iAR), resulting in dissociation of heat-shock-protein 90 (HSP 90) 
and other chaperons from the receptors [5]. Subsequently, unprotected iAR dimerize and move to the 
nucleus, where they are phosphorylated at several serine residues and continue to recruit several 
co-activators like cAMP response element binding protein (CREB)-binding protein (CBP), 
p300/CBP-associated factor (p/CAF) and steroid receptor coactivator 1 (SRC-1), etc. [5,7,86]. In the 
following step, the receptor-coactivator-complexes bind to specific androgen-response-elements 
(ARE) on the DNA [5], leading to chromatin remodelling and recruitment of RNA-polymerase II [7]. 
The enzyme transcribes target DNA-regions into mRNA which, after translation, results in 
production of different protein products (Figure 1). These are supposed to promote relevant 
changes in different tissues [5]. Mechanisms of iAR activation are described more in depth by 
Kicman et al. [6], Li et al. [7] and Bennett et al. [5]. 
Results of activation in productive tissue are increased levels of prostate specific antigen (PSA) 
and production of probasin [5]. Muscle tissue is supposed to produce more protein while retaining 
136 
AIMS Molecular Science  Volume 5, Issue 2, 131–159. 
nitrogen and thereby increasing its size and strength [2,7,87]. However, only very limited numbers of 
studies display the finally achieved enhancement in sports performance. Evidence has been provided 
that bone tissue answers stimulation by increased erythropoiesis, elevated cell proliferation and 
increased synthesis of growth factors [23]. This signalling cascade is displayed in Figure 1. 
2.1.2. Anti-catabolic effects of AAS 
Evidence is increasing, that additional anti-catabolic effects of AAS are mediated through 
inhibition of the binding of endogenous ligands to glucocorticoid receptors [6,23]. Physiological 
agonists on these receptors are glucocorticoids such as cortisol, which mediate various effects in the 
body, mainly related to metabolism of carbohydrates and lipids. They are considered as most important 
stress hormones in mammals (including humans) besides adrenaline and noradrenaline [17]. The initial 
mechanism mediating glucocorticoid-induced processes are analogous to that described for the 
genomic AR response. The resulting specific mediator proteins promote amino acid degradation, 
nitrogen excretion and reduction of mass in muscle tissue in order to provide the energy, which 
might be needed in stressful situations [17–19,23]. 
According to Kicman et al., binding of testosterone or other AAS to the glucocorticoid receptor 
may inhibit binding of GR agonists, and thereby result in anti-catabolic (anabolic) effects like 
nitrogen retention and muscle hypertrophy (Figure 2) [6]. 
 
Figure 1. Genomic action of anabolic androgenic steroids mediated by androgen receptor 
binding. 
137 
AIMS Molecular Science  Volume 5, Issue 2, 131–159. 
 
Figure 2. Anti-catabolic activity of anabolic androgenic steroids by competitive binding 
to glucocorticoid receptor. 
2.1.3. Non-genomic actions of AAS 
Rapid, non-genomic actions of testosterone are mediated through several membrane-located 
receptors and ion channels, including endothelial growth factor receptor (EGFR), membrane-located 
androgen receptors (mAR), sex hormone-binding globulin receptor (SHBGR) and calcium-ion 
channels [5,9,12]. Binding of AAS to these receptors leads to activation of several second messenger 
signalling cascade pathways (Figure 3). Those pathways result in production of mediators, which 
promote anabolic changes through direct interaction with cells in various tissues, with very short 
response times [5,7]. In addition to that, intracellular androgen receptors are also stimulated by end 
products of second messenger signalling cascades, facilitating an increase in transcriptional 
activity [9]. Protein products of activated second messenger signalling cascades are also supposed to 
lead to transcription of specific DNA gene regions [9]. 
Binding of AAS to EGFR is suggested to promote activation of Ras-Kinase [14], which itself 
activates MAP-Erk-Kinase (MEK) [5,9,11]. Subsequently, MEK phosphorylates extracellular 
signal-regulated protein kinases 1/2 (ERK 1/2), which then translocate to the nucleus and 
phosphorylate transcription factors like the ETS domain-containing protein ELK1 [12,14]. Bound 
mARs seem to stimulate the tyrosine kinase c-SRC, which can either also phosphorylate Ras, leading 
to ERK 1/2 activation, or interact with membrane-located adenylylcyclases (AC) [12]. AC recruit 
adenosine triphosphate (ATP), turning it into the second messenger cyclic adenosine-monophosphate 
(cAMP). cAMP activates proteinkinase A (PKA) by binding to its regulatory subunit. PKA then 
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phosphorylates specific target proteins with its catalytic subunit, e.g., cAMP response element 
binding protein-1 (CREB-1) [14]. 
Upon phosphorylation, CREB-1 interacts with a cAMP response element on the regulatory 
region of a gene and increases its transcription [52]. It should be noted that phosphorylation through 
PKA not necessarily leads to activation but may also result in inactivation of proteins like Ras 
homolog family member A (RhoA) in smooth muscle cells. Phosphorylation of RhoA by PKA 
promotes dephosphorylation of myosin light-chains (MLC) in smooth muscle which in turn prevents 
constant muscle contraction [88]. 
 
Figure 3. Signalling cascade on non-genomic action of anabolic androgenic steroids. 
In addition to activation through cAMP, PKA can also be stimulated by calmodulin which itself 
is activated by binding of calcium ions [9]. Last but not least, sex hormone binding globulin 
receptors (SHBGR) have been proposed to also use the AC-PKA-signalling pathway in order to 
modulate target gene transcription [9,12,14,15]. Publications also propose non-genomic signalling 
through intracellular androgen receptors (iAR) in a kind of feedback mechanism: Phosphorylated 
ERK 1/2 is proposed to stimulate iAR resulting in stimulation of MEK which then again increases 
ERK 1/2 activation [5]. Upregulation of transcriptional activity through iAR can also be observed as 
an answer to ERK 1/2 stimulation [5]. Resulting reactions in tissue can be divided in those 
immediately mediated by ERK 1/2 and those resulting from gene transcription. Immediate changes 
are observed in muscle cells which increase force in fast twitch fibres and decrease force in slow 
twitch fibres. Gene transcription mediated modulations include increased gonadotropin releasing 
hormone (GnRH) secretion from the hypothalamus and metabolism changes in osteoblasts. Those 
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enhance cell proliferation while reducing apoptosis [9,10]. All proposed mechanisms (Figure 3) may 
lead to anabolic changes in tissue, promoting muscle hypertrophy [3]. 
There are also reports that propose AAS to activate the PI3K pathway via a non-genomic 
mechanism, in which stimulated AR phosphorylate the p85-subunit of PI3K [5]. Due to its confirmed 
relevance in ER-β mediated signalling, this pathway is presented in detail in chapter 2.3 and 
Figure 4. 
2.1.4. Hypothalamus pituitary axis feedback loop 
The administration of AAS directly affects the production of endogenous hormones via 
feedback mechanisms on the hypothalamic pituitary gonadal axis (HPA) [89]. The HPA is regulated 
by negative feedback mechanisms from AR binding in the hypothalamus [90,91]. This results in 
decreased GnRH synthesis in the hypothalamus, decreased gonadotropin secretion in the pituitary 
gland, as well as a non-steroidal feedback of inhibin B on FSH secretion in the pituitary gland [92]. 
Already one single dose administration of AAS was reported to result in decreased serum LH and 
inhibin B levels, while prolactin and IGF-1 levels increased after prolonged administration [87,93]. 
This also concomitantly reduced endogenous production of sex steroids including the endogenous 
AAS testosterone. Even after 12 weeks after withdrawal initial levels were not recovered again [93]. 
2.2. Selective androgen receptor modulators (SARMs) 
More recently, selective androgen receptor modulators (SARMs) are under investigation for use 
as muscle building agents. They are developed with the intention of improving physical function and 
bone health without adversely affecting the prostate and cardiovascular system. The exact 
mechanism of their tissue selectivity still remains uncovered until now [39]. A tissue-selective 
modulation of signalling pathways is mainly considered to occur due to availability of 
coregulators [94]. Additionally, tissue-specific expression of various steroidogenic and metabolic 
enzymes as well as transcription factors are discussed to contribute to the tissue selectivity [39]. For 
further reading we recommend the reviews of Narayanan et al. and McEwan [39,95]. Different 
chemical classes have been investigated as non-steroidal SARMs until now. Most of them belong to 
the arylpropionamides or quinoline derivatives. It is reported that signalling of enobosarm (SARM 
S-22) is mediated through Src kinase, MEK-1/2 or MEK-3, ERK and p38 mitogen-activated protein 
kinase (MAPK) pathways [96]. Further research is needed to elucidate the mechanism of action in 
SARMs. 
2.3. Estrogen receptor β (ER-β) agonists 
It is reported that also an activation of the estrogen receptors (ER) results in muscle 
hypertrophy [97–99]. More specifically, investigations could identify the ER-β as target for 
mediating this effect [99,100]. Several classes of substances are reported as ER-β agonists, with lots 
of the recently investigated being plant derived [101–115]. To the best of our knowledge 
diarylpropionitril [2,3-bis (4-hydroxyphenyl)-propionitrile] and 8β-VE2 were the first selective ER-β 
agonists that were reported in literature [116–118]. Currently, clinical trials are performed using the 
ER-β agonist LY500307 as well as phytoestrogens epigallocatechin gallate and S-equol 
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(www.clinical trials.com, accessed Nov 29th, 2017). Furthermore, some phytoestrogens such as 
ecdysterone and daidzein showed strong selectivity towards the ER-β, which even exceeds the 
selectivity of S-equol. However, a considerably lower activity of the phytoestrogens is seen in 
comparison to estradiol or the synthetic ER-β agonists mentioned above [33,112,114,117,119–121]. 
Ecdysterone is reported to influence adipose and muscle tissue, resulting in increased muscle mass 
and body weight while decreasing visceral fat mass [33,37,122]. In animal studies, increase of 
physical performance without training, increased synthesis of myofibrillar proteins in muscle, 
increased protein content and growth in liver and kidney have been reported [21]. However, some 
phytoestrogens are proposed to mediate anabolic effects through membrane-bound ER-β 
receptors [33], without causing apparent adverse androgenic effects [21]. Furthermore, in a recent 
study, same doses of the phytoecdysteroid ecdysterone elicited stronger hypertrophic effects in 
mouse myoblastoma cell line C2C12 derived myotubes than the AAS metandienone, estradienedione 
and SARM S1 [122]. This implies a strong potency of phytoecdysteroids in inducing muscle 
hypertrophy and provides hope for the opportunity to evoke anti-catabolic actions already in small 
doses. Quercetin, reported as unselective ER agonist, was also reported to increase the 
cross-sectional area and minimal fibre diameter in mice. This effect was even more pronounced at 
co-supplementation of whey protein [123]. 
Depending on tissue, different signalling mechanisms may be involved (Figure 4). In 
adipocytes, peroxisome-proliferator activated receptor-gamma (PPAR gamma), which promotes 
lipid uptake and adipogenesis, is supposed to be inhibited [34,37,124,125]. This results in 
increased lipolysis and even apoptosis of adipose cells. Also, adipogenesis and lipid 
accumulation is reported to be inhibited, leading to a decrease in visceral fat, adipocyte size and 
an overall decrease in serum lipid concentration. Changes in muscle tissues after activation of 
ER-β are mediated through the PI3K/Akt pathway (Figure 4) [21,32,33,126–128]. After 
activation of PI3K, phosphatidylinositol-4,5-bisphosphate (PIP2) is recruited and turned into 
phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 then acts as lipid binding site on the cell 
membrane, inducing the recruitment of the serine/threonine kinase Akt. After being recruited to the 
cell membrane, Akt is phosphorylated by the kinase PDK-1 [129]. Bodine et al. 
propose induction of protein synthesis through Akt via phosphorylation of glycogen synthase  
kinase 3 (GSK-3), resulting in its inhibition [127]. Inhibited GSK-3 releases elF2B, a transcription 
factor which upregulates protein synthesis [56,130]. Another important target of Akt is mTOR, 
which leads to activation of p70 ribosomal protein S6 kinase (p70S6K) and inhibition of 
PHAS-1/4E-BP1 through phosphorylation [56,130]. Activated p70S6K also promotes protein 
synthesis while PHAS-1/4E-BP1 is supposed to mediate translation initiation after release of the 
translation initiation factor elF4E [56,130]. After binding of elF4E to elF4G, initiation of 
translation is facilitated [56,130]. It is also proposed that Akt inhibits forkhead O transcription factor 
(FOXO), which mediates production of the ubiquitin ligases MuRF1 (muscle ring finger protein 1) 
and MAFbx (muscle atrophy F-box protein) [35,126,131]. Evidence is increasing that MuRF1 and 
MAFbx play a key role in muscle atrophy [35,126,131]. Inhibiting FOXO, and thus the transcription 
of MuRF1 and MAFbx, indirectly favours muscle growth by decreasing muscle atrophy [126,132]. 
Akt also prevents apoptosis of muscle cells by phosphorylating Bcl-associated death agonist (BAD), 
which is highly important for apoptotic processes [32,133]. Further information on the PI3K pathway 
and downstream targets of Akt is provided in other publications, e.g. [56,127,129,134–136]. 
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Overall, resulting effects in muscle cells include increased protein synthesis, promotion of 
IGF-1 synthesis, increased insulin sensitivity, expanded apoptosis, and improved utilisation of 
glucose and lipids, while reducing protein degradation [21,33,34,37]. 
 
Figure 4. Estrogen receptor β mediated signalling pathways leading to muscle 
hypertrophy. 
2.4. β2-Adrenergic agonists 
β2-Adrenergic agonists are synthetic analogues of adrenaline that are therapeutically used as 
bronchodilating agents in asthma bronchiale or chronic obstructive pulmonary disease (COPD). They act 
as sympathomimetic agents primarily targeting the β2-adrenoreceptor, a Gαs-GPCR located in the cell 
membrane (Figure 5) [41,52,137]. Further information about different types of β-adrenergic receptors 
and their effects on tissue can be found in the publication by Mersmann et al. [52]. Stimulation of 
β2-adrenergic receptors leads to AC activation and thereby increase cAMP production [52]. In smooth 
muscles this leads to relaxation, which is the main therapeutic concept of β2-adrenergic agonists. 
However, the increased cAMP also results in promotion of the cAMP-proteinkinase A signalling 
pathway described in the section about non-genomic actions of AAS and actions of ER-β 
agonists in chapters 2.1.3 and 2.3. The Akt/mTOR signalling pathway is triggered via PI3K, 
mediated upon β2-adrenergic activation by Gαi-associated Gβγ dimer [138,139]. Therapeutically 
desired the inhibition of PI3K reduces interleukin 25 (IL-25) mediated airway 
hyperresponsiveness and inflammation [140]. Downstream, it results in an increased expression of 
ribosomal proteins by stimulation of p70s6K [141,142]. At the same time, mTOR inhibits the eukaryotic 
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initiation factor 4E binding protein-1 (4E-BP1), itself an inhibitor of protein translation [143]. Studies on 
clenbuterol-treated rats showed increased p70s6K and reduced 4E-BP1 activity [144]. Since the 
Akt/mTOR signalling pathway (Figure 4) plays a role in the regulation of muscle growth [145], it was 
also possible to antagonize the anabolic effects of clenbuterol by means of rapamycin, an m-gate 
inhibitor [146]. A protein called exchange protein directly activated by cAMP 1 (Epac1) was introduced as 
important player in clenbuterol induced hypertrophy by Okumura et al [147]. Differential effects of 
clenbuterol on fast- and slow-twitch muscle fibres were explained by the differences in downstream 
regulated hydrolysis of cAMP [148], which is regulated by phosphodiesterase 4 [149]. In ractopamine fed 
pigs type I and IIA fibre diameters were increased [150]. However, chronic clenbuterol administration is 
associated with reduced contractile efficiency, especially in fast contracting muscles [151]. In addition to the 
activation of m-gate, Akt is also able to directly inhibit FOXO [152,153]. However, it was also reported that 
clenbuterol does not act via Act/FOXO but via Act/mTor pathway and IGF1 expression [154]. As 
already mentioned in chapter 2.3. FOXO is a transcription factor that promotes transcription of the 
MuRF1 (Muscle RING finger 1) and MAFbx (muscle atrophy F-box) genes. MuRF1 and MAFbx 
encode ubiquitin ligases that are expressed in muscle atrophy [145,155]. Thus, by β2-receptor 
activation, skeletal muscle growth and a muscle-protective effect can be assumed which was 
successfully demonstrated for the β2-agonist formoterol in arthritic rats [156]. Comparable effects 
are reported in prolonged treatment of with atomoxetine, a selective noradrenaline reuptake 
inhibitor (NARI) [157]. 
Furthermore, in non-muscular tissues, phosphorylation and de-phosphorylation of various 
proteins is suggested to result in changes in hormonal profile and an increase in blood flow, which 
enables transportation of hormones, substrates and energy sources for protein synthesis to muscular 
tissue [52,158]. In fat tissue PKA modulates phosphorylation, resulting in increased lipolysis and 
triacylglycerol hydrolysis, while lipogenesis is decreased [52]. It has to be noted that effects on 
adipose tissue regarding lipogenesis and lipolysis seem to vary between β2-adrenergic drugs. For 
example, Peterla et al. [159] found out, that clenbuterol decreases lipogenesis but has no effect on 
lipolysis. They report data from an in vitro study on lipolysis and lipogenesis by porcine adipose 
tissue when treated with different β2-adrenergic agonists [159]. Also Yang et al. [158] reported an 
inhibition of fatty acid synthesis concomitant with a promotion of glycogenolysis in the liver of 
rodents. Finally, muscle cells seem to increase protein synthesis and glycogenolysis, while reducing 
the rate of glycogen synthesis and protein degradation [52,137]. These hormone-mediated effects are 
supposed to be enhanced by direct stimulation of muscle tissue through PKA [52]. It was reported 
that CREB is phosphorylated in this signalling cascade. This transcription factor subsequently binds to 
defined cAMP response elements (CRE) and thus influences the transcription of diverse genes [160]. 
Among others, the expression of neuron-derived orphan receptor 1 (NOR1) is increased [161]. 
Inhibition of NOR1 mRNA by siRNA, in turn, led to a highly significant increase in myostatin 
mRNA in vitro [66]. Myostatin is a representative of the transforming growth factor β (TGF-β) 
family and is known as negative regulator of muscle growth [59,60]. Thus, β2-adrenergic agonists 
most likely indirectly influence the level of myostatin and thus, also muscle growth via NOR1. 
Further information on myostatin is available in chapter 2.6. In summary, resulting effects of 
β2-adrenergic agonists on body composition include an overall increase in body weight and muscle 
mass as well as a decrease in body fat (Figure 5) [52,162–164]. 
Not all β2-adrenergic agonists seem to induce these effects to the same degree. It has to be considered, 
that the intensity of effect depends on the chemical structure of the drug and the route of application. 
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Intraperitoneal application is suggested to be the only efficient for salmeterol while clenbuterol also 
increases muscle growth when given orally [42]. Moore et al. also report that β2-adrenergic agonists need a 
long duration of application until actually evoking these metabolic changes [23]. 
Finally, one has to be aware, that very few studies in humans have been conducted and that 
relevant studies mostly report results of animal testing or from usage in production animals. In 
addition to that, major differences in resulting effects have been noticed between different animal 
species [52]. Thus, findings in animal studies may not be directly transferable to human tissue, and 
the relevant metabolic changes in human tissues still need to be elucidated. 
 
Figure 5. cAMP signalling after β2-adrenergic receptor activation. 
2.5. Growth-hormone, IGF-1 and insulin 
Peptide-hormones like somatotropin (growth hormone, GH), insulin-like growth factor-1 (IGF-1) 
and insulin are also reported as essential mediators of muscle hypertrophy [35,54,55,129,165–167]. GH, 
physiologically secreted by the anterior hypophysis after stimulation by the hypothalamus through 
growth hormone releasing hormone (GHRH) [35], acts mainly as trigger for IGF-1 release from the 
liver [35,54,168]. Only recently, GH has been reported to increase serum decorin, a protein which 
interacts with various growth factors [169]. It is reported to bind to myostatin and promote 
hypertrophy by downstream pathways (chapter 2.6.) [170]. GH itself does not seem to be able to 
induce long-term increases in muscle mass without stimulation through exercise [35]. IGF-1 is 
mainly secreted in the liver, triggered by GH pulses that originate from the anterior hypophysis. This 
fraction of IGF-1 is called circulating IGF-1 (cIGF-1), indicating its separation from muscular IGF-1 
(mIGF-1), which also influences body composition but is released directly from muscular tissue [35]. 
mIGF-1 can influence proximate muscle cells via paracrine signalling or enhance the stimulation of 
its cell of origin by autocrine mechanisms (Figure 6) [35,54,135,166,167,171]. Evidence is increasing, 
144 
AIMS Molecular Science  Volume 5, Issue 2, 131–159. 
that the mIGF-1 isoform is much more potent in inducing muscle hypertrophy than the cIGF-1, resulting 
from GH-stimulation [35,54,133,167,172,173]. In contrast to that, cIGF as well as GH are thought to be 
important in reducing catabolic activity by reducing the negative nitrogen balance when the patient is 
exposed to a calorific deficit [35]. Thus, Velloso et al. report that GH and cIGF are highly important in 
patients suffering from catabolic conditions and less important for muscle growth in healthy individuals 
such as athletes [35]. Upstream targets for IGF-1 also allow for induction of muscle hypertrophy. 
Recently, Jang et al. [174] showed that the natural flavone Apigenin enhances muscle hypertrophy via 
protein arginine methyltransferase 7 (Prmt7) increase, GPCR56 expression and subsequent activation of 
the IGF-1 pathway. Furthermore, Apigenin induced Prmt7 increase is also reported therein to induce 
muscle cell differentiation by regulation of p38 MAPK and myoblast determination protein (MyoD). 
 
Figure 6. IGF-1 and insulin induced muscle hypertrophy involving IGF-1 receptor, 
insulin receptor and Ca2+ channel signalling. 
Several signalling pathways are discussed after IGF-1 binding (Figure 6), including the 
PI3K/Akt pathway, that was already mentioned in the section about ER-β agonists (chapter 2.3, 
Figure 4) [35,54,55,129,133,166]. PI3K is activated after mIGF-1 or cIGF-1 have bound to the IGF-1 
receptor (IGF-1R), resulting in phosphorylation of insulin response substrate (IRS) 1 via tyrosine 
kinase activity [35]. IRS-1 then phosphorylates PI3K, starting the signalling cascade [35]. In addition 
to activation through IGF-1, insulin is also discussed to activate the PI3K signalling cascade [35,173,175] 
after either binding to insulin receptors (IR) with high affinity or to IGF-1Rs with lower affinity [135]. 
Conversely, IGF-1 is also supposed to be able to activate IRs with low affinity [35,135]. After 
binding, insulin receptors phosphorylate IRS-1 and IRS-2 through their intrinsic tyrosine kinase 
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activity, stimulating their binding to and subsequent activation of PI3K [56]. Downstream targets of 
the PI3K pathway are the transcription factors elF2B, elF4E and p70S6K (chapter 2.3). They are also 
responsible for changes in protein expression after IGF-1 or insulin administration [56,129,173]. 
While many researchers think of Akt as an essential mediator in activation of mTOR and p70S6K as 
part of the PI3K pathway [129,173], other studies imply that these downstream targets are activated 
via mechanisms independent from Akt mediation [133]. 
As results of these changes in muscle cells, an increased DNA-synthesis, accumulation of 
protein and an increased production of mIGF, which results in amplifying the effects of cIGF 
through paracrine and autocrine mechanisms, are reported [35,172]. Furthermore, an activation of 
satellite cells, which are proposed to fuse with already existing myofibers, and thereby enlarging 
muscular tissue, is discussed [35,54,135,166,171,176]. In analogy to the PI3K pathway discussed in 
the section on ER-β agonists, IGF-1 and insulin are also reported to antagonize muscle atrophy 
through Akt dependent inhibition of MAFbx and MuRF1 [173]. A different approach to explaining 
IGF-mediated muscle hypertrophy implies involvement of the Ras-Raf signalling cascade, resulting 
in cell proliferation [133,135,166]. It has to be noted that the relevance of this signalling pathway 
is still unclear. Some researchers propose that the MAPK pathway actually has to be inhibited for 
achieving muscle hypertrophy in skeletal muscle [133]. Another proposed mechanism of action 
involves signalling through ligand-dependent calcium channels (Figure 6). This may also 
facilitate cell differentiation through the serine phosphatase calcineurin, resulting in muscle 
hypertrophy [133,167,177–180]. In analogy to signalling in ER-β stimulated cells, binding of mIGF 
or cIGF to these ion channels triggers their opening. Calcium influx activates calcineurin, which forms a 
complex with calcium ions and calmodulin. This complex then activates nuclear factors of activated 
T-cells (NFATs), transcription factors, promoting cell proliferation and growth of muscular tissue via 
dephosphorylation [133,179,181]. More detailed information regarding downstream targets of this 
pathway has been provided by Musaro et al. and Swoa et al. [171,182]. 
It has to be noted, that the importance of the NFAT pathway still remains unknown with several 
controversial studies being published. While some studies [179–181] find this pathway to be highly 
important in promoting hypertrophy especially in cardiac myocytes, other researchers find the 
calcineurin pathway of lower importance or even antagonised after IGF-1 stimulation [55,171,182]. 
Independent from effects in muscle tissue, various effects of GH on body composition and 
metabolism have also been reported. It is supposed, that the hormone mediates lipolytic activity and 
effects on collagen and bone turnover [35]. This may lead to improved performance without 
evolvement of muscle hypertrophy and could be a possible explanation for the widespread use of GH 
for doping purposes despite the lack of effects on muscular tissue. 
2.6. Myostatin inhibitors 
As already mentioned in the section about β2-adrenergic agonists (chapter 2.4), myostatin (also 
called growth differentiation factor 8, GDF-8) is an important and potent regulator of muscle 
homeostasis (Figure 7). It is highly expressed in skeletal muscle, where it conveys its signals through 
the extracellular activin type IIB receptor (ActRIIB). ActRIIB is expressed as a heterodimer together 
with either activin-like kinase 4 (ALK4) or activin-like kinase 5 (ALK5) [183]. Both kinases belong 
to the group of serine/threonine kinases and lead to the phosphorylation of transcription factors 
Smad2 and Smad3 upon activation. Phosphorylated Smad2 and Smad3 both form heterodimers 
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together with Smad4 and inhibit the transcription of various genes involved in muscular proliferation 
and differentiation after moving to the nucleus [184,185]. As the relevance of myostatin in various 
diseases involving muscle atrophy and sarcopenia has become increasingly evident in recent years [186], 
inhibition of myostatin seems a promising approach for novel therapeutic options. Several facts 
contribute to myostatin being an attractive target for drug therapy: First, its presence has been clearly 
correlated with loss of muscle mass and muscle volume in various animal studies [184]. Second, the 
high abundance of myostatin in skeletal muscle, when compared to other tissue, raises hope for high 
specificity and few off-target effects of possible myostatin-inhibiting agents. Third, its signalling 
mechanism provides multiple possible options for disruption. As myostatin is secreted into the 
bloodstream, the circulating protein can be bound by neutralizing antibodies or soluble ActRIIB 
receptors (Figure 7). In addition to that, myostatin binding proteins like myostatin propetide, 
follistatin and the follistatin related proteins follistatin related gene (FLRG) as well as growth 
and differentiation factor-associated serum protein-1 (GASP-1) may be used to inactivate 
myostatin [184]. Increased follistatin levels were also reported to act on mTOR most likely via 
SMAD3, which is also found to act independently from myostatin inhibition [187] and by the 
recently reported bone morphogenetic protein (BMP) signalling pathway [188]. An interconnection 
with the IGF-1R pathway is suggested and Barbé et al. [189] found IGF-1 and insulin deficiency to 
attenuate follistatin induced muscle hypertrophy. While application of myostatin binding proteins 
or antibodies may be promising approaches, administration of soluble ActRIIB receptors should 
be considered with caution. Side effects like skin telangiectasias and reversible nose bleedings 
have been reported in a clinical trial of the human ActRIIB-Fc ACE-301 in boys suffering from 
Duchenne muscular dystrophy (DMD), resulting in termination of the agents development [186].  
 
Figure 7. Myostatin signalling in muscle atrophy and possible therapeutic targets. 
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Furthermore, while studying the administration of an activin receptor fusion protein in a mouse model, 
the increase in muscle mass was associated with elevated serum levels of corticosterone and 
deteriorated hyperglycemia [190]. For the moment, monoclonal neutralizing antibodies targeting 
myostatin seem to be the most promising approach, with ongoing (PF-06252616, NCT02310763) and 
recently completed (LY2495655, NCT01524224) clinical trials (according to clinicaltrials.gov, 
accessed Nov 29th, 2017). 
2.7. Future directions 
Besides by small molecules and larger proteins like insulin and IGF-1, muscle composition can 
also be controlled by epigenetic regulation, which has gained the interest of researchers in recent 
years. Epigenetic regulation can be defined as heritable structural modifications of DNA and histones, 
resulting in modified gene activity without altering the DNA sequence [191]. Interestingly, in 
contrast to changes in the genetic code, changes in epigenetic structures show highly dynamic 
characteristics and seem to be directly influenced not only by environmental factors but also by life 
circumstances such as nutrition and physical activity. The most prominent epigenetic changes 
include DNA methylation/demethylation, histone acetylation/deacetylation and microRNA 
expression. DNA methylation by DNA methyltransferases within so-called CpG-islands, regions rich 
in cytosine-phosphate-guanine (CpG) dinucleotides, results in decreased gene-expression while 
demethylation allows gene activity [192]. Acetylation of lysine residues of the very basic histone 
proteins by histone acetyltransferases (HAT) decreases their alkaline properties and lowers their 
affinity to the acidic DNA strands, thus allowing proteins of the transcriptional machinery to gain 
access to the DNA. Conversely, deacetylation by histone deacetylases (HDACs) leads to gene 
silencing by providing a tightly packed chromatin structure. Last but not least, microRNAs are short 
single-strand RNA molecules, which can suppress the post-transcriptional processing of targeted 
mRNAs by binding to specific sequences in their untranslated regions [193]. It has to be noted, that 
one microRNA can target many different mRNAs and mRNAs can be susceptible to various 
microRNAs. In recent time, the epigenetic regulation of genes involved in muscle generation, 
differentiation and maintenance has been identified as important factor not only in embryonic 
myogenesis but also later in life. One example is the control of activity of muscle satellite cells, 
where differentiation processes have been reported to be repressed by high DNA methylation [191]. 
Furthermore, high activation of HATs and simultaneous inactivation of HDACs in 
undifferentiated myoblasts, allowing access of transcription factors for further differentiation, 
has been described [191]. Further information on current knowledge on the mechanisms of these 
DNA and histone modifications as well as thorough descriptions of the relevant enzymes involved is 
reviewed by Sincennes et al. [194]. In this review, the authors also mention the potential of HDAC 
inhibitors as therapeutic agents against muscular dystrophy. Amongst other factors, the relevant 
effect is supposed to result from an increased expression of follistatin after administration of HDAC 
inhibitors. As potent inhibitor of myostatin and other members of the TGF-β superfamily, follistatin 
has a direct role in compensating muscular loss. Therefore, HDAC inhibitors enter at least in part the 
same mechanistic pathway as myostatin inhibitors (2.6). At the moment, three clinical trials with the 
HDAC inhibitor givinostat are in the recruitment phase: One phase-II study for the treatment of 
Becker muscular dystrophy (NCT03238235) and two phase-III studies focusing on patients with 
DMD (NCT02851797, NCT03373968) (according to clinicaltrials.gov, accessed Mar 18th, 2018). 
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Another phase-II study with givinostat with patients suffering from DMD has been completed in 
November 2017, with results remaining to be published (NCT01761292). Finally, some miRNAs 
are widely expressed in muscle tissue where they are supposed to be of high importance during 
muscle development. The probably most relevant miRNAs in this context are miR-1, miR-133 
and miR-206 [195]. While miR-1 and miR-206 are supposed to facilitate myoblast-to-myotube 
differentiation in skeletal muscle, miR-133 seems to promote myoblast proliferation and inhibit 
differentiation [191]. Further insight into the mechanisms of these miRNAs can be found in the 
articles by Townley-Tilson et al. [195], Proctor et al. [196] and Yu et al. [197]. There are many other 
tissue-specific and non-tissue-specific miRNAs involved in muscle regulation. Although the current 
insight into their respective role and importance is limited due to the lack of human studies, 
designing specific miRNAs could be a promising approach for therapeutic use after further research 
has been conducted.  
3. Conclusions 
The substance classes discussed in this review are considered to activate several different 
signalling cascades, which can generally be divided in two groups: Those, which cause long-term 
changes and need hours to days until changes in tissue emerge, and those who mediate so-called 
rapid actions, with responses typically being detectable after seconds to minutes. It was observed, 
that the actions caused by a certain drug type normally cannot be assigned to one of these groups 
only. It has to be considered, that most substances affect tissue through multiple pathways, although 
differing in the extent to which they do so. Moreover, rapid actions may also lead to change of 
transcriptional activity. This happens, when second messenger molecules, which have been 
generated through rapid actions, stimulate transcription factors, which subsequently mediate changes 
in gene expression [5]. One example is the activation of the transcription factor Elk-1 through 
stimulated ERK1/2, which itself is considered to be activated via non-genomic signalling [5]. 
Another observation to be considered is that even though different substance classes bind to different 
receptors, they often lead to similar signalling pathways and downstream targets. For instance, the 
PI3K/Akt pathway, promoting protein synthesis and inhibiting protein degradation, is reported to be 
activated by ER-β and β2-adrenergic agonists, IGF-1, insulin and indirectly through GH. PI3K 
activation through non-genomic actions of AAS, resulting in phosphorylation of the PI3K-p85 
subunit by AR is also proposed [5]. Besides this, the MAPK pathway is supposed to not only be 
activated via non-genomic action of AAS but also through IGF-1 stimulation. In addition to that, the 
signalling pathways activated by one drug can also lead to activation of such downstream targets, 
that are normally “main-targets” of other substance types: For instance, it has been reported, that 
non-genomic actions of iAR can lead to increased GnRH production in the hypothalamus which in 
turn increases GH and IGF-1 production [9,10]. Thus, IGF-1 dependent mechanisms may indirectly 
be activated by administration of AAS and ER-β agonists. 
Even though several signalling mechanisms have already been elucidated to great extent, there are 
still areas, where more research is strongly needed. Such research for instance could focus on the role 
of the calcineurin pathway in cells stimulated by IGF-1 or the mechanisms by which AAS influence 
tissues via calcium dependent non-genomic actions. Better insights into the biochemical mechanisms 
facilitating muscle hypertrophy may help to predict desired and adverse effects of already known but 
also newly emerging drugs. This will not only help to reduce the risk for athletes, which illegally use 
149 
AIMS Molecular Science  Volume 5, Issue 2, 131–159. 
anabolic substances to enhance their performance, and anti-doping laboratories to quickly adapt their 
analytical methods for detection of potentially misused drugs, but also to find possible drugs for 
treating cachexia and muscle atrophy while minimizing the risk of adverse effects at the same time. 
With the current knowledge on different substance classes, ER-β agonists, SARMs, myostatin 
and HDAC inhibitors appear as most promising candidates for therapeutic use. However, finally it 
has to be mentioned that pharmacological intervention with the intention of performance 
enhancement in sports is considered as unethical and against a fair and clean competition. 
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